Summary of Daré Bioscience Q3 2025 Earnings Call

1Key Financial Results and Metrics

Cash and Cash Equivalents:: Approximately $23 million.

Working Capital:: Approximately $3.8 million.

Net Proceeds from Stock Sales:: About $18.7 million.

Grant Payments Received:: Total of $7.3 million.

General & Administrative Expenses:: $2.5 million (up from $2 million in Q3 2024).

Research & Development Expenses:: $1.2 million (down 56% from $2.7 million in Q3 2024), primarily due to nondilutive funding and reduced manufacturing costs.

2Strategic Updates and Business Highlights

Dual Path Strategy:: Daré is focusing on commercializing proprietary formulations via 503B compounding while pursuing FDA approvals.

DARE to PLAY Sildenafil Cream:: Expected to launch through a 503B outsourcing facility by December 2025, marking a significant milestone in women's sexual health.

Clinical Pipeline:: Advancements in programs targeting contraception (Ovaprene), HPV (DARE-HPV), and menopause (DARE to RECLAIM).

DARE to RESTORE:: Planned launch of vaginal probiotic products in Q1 2026.

Partnerships:: Collaborations with Medvantx for pharmacy services and logistics, and Rosy Wellness to enhance product awareness.

3Forward Guidance and Outlook

Revenue Generation:: Initial revenue expected from DARE to PLAY in Q4 2025.

Future Products:: DARE to RECLAIM (hormone therapy ring) anticipated in early 2027, with both 503B compounding and FDA approval pathways being pursued.

Clinical Trials:: Continued focus on grant-funded programs with expected completion of Ovaprene enrollment in 2026.

4Bad News, Challenges, or Points of Concern

Regulatory Risks:: Ongoing discussions with the FDA regarding the approval pathways for various products, which could impact timelines.

Market Competition:: The need for broader partnerships and marketing strategies to effectively penetrate the women's health market.

Funding Limitations:: Current limitations on the use of the ATM (at-the-market) program due to market cap restrictions.

5Notable Q&A Insights

FDA Guidance on Hormone Therapy:: Positive feedback on recent FDA changes regarding hormone replacement therapy, which could benefit DARE to RECLAIM.

Partnerships for Awareness:: Emphasis on the need for broader partnerships to increase awareness and accessibility of DARE to PLAY.

R&D Prioritization:: Focus on advancing products with clear paths to market, particularly those supported by grant funding, while evaluating additional R&D investments carefully. Overall, Daré Bioscience is positioned for growth with a strong pipeline and strategic initiatives aimed at addressing women's health needs, despite facing regulatory and market challenges.